DOCSLIB.ORG

VERSATIS® 5% W/W Dermal Patch

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
VERSATIS® 5% W/W Dermal Patch VERSATIS 5% w/w Dermal Patch Lidocaine (Lignocaine) CONSUMER MEDICINE INFORMATION What is in this leaflet VERSATIS Dermal Patch is available only with a doctor's prescription. If it has expired or is damaged, Read this leaflet carefully return it to your pharmacist for before you start using this There is no evidence that this disposal. medicine. medicine is addictive. If the package has become This leaflet answers some common This medicine is not expected to damaged, the dermal patches may questions about VERSATIS Dermal affect your ability to drive a car or dry out and become less sticky. Patch. operate machinery. Before you start to use it It does not contain all of the Before you apply available information. It does not VERSATIS Dermal Patch Tell your doctor if you are take the place of talking to your allergic to any other medicines, foods, dyes or preservatives. doctor or pharmacist. When you must not use it Tell your doctor if you have, or All medicines have benefits and Do not use VERSATIS Dermal risks. Your doctor has weighed the have had, any medical Patch if you have an allergy to: conditions, especially the risks of you using VERSATIS Dermal any medicine containing lidocaine Patch against the benefits they following: any of the ingredients listed at severe liver disease expect it will have for you. the end of this leaflet, especially severe kidney disease methyl hydroxybenzoate and severe heart problems If you have any concerns about propyl hydroxybenzoate using this medicine, talk to any other medicines similar to Tell your doctor if you are your doctor or pharmacist. lidocaine such as bupivacaine, pregnant or plan to become etidocaine, mepivacaine or pregnant or are breast feeding. Keep this leaflet with your prilocaine. medicine. Your doctor can discuss the risks You may need to read it again. Some of the symptoms of an and benefits involved. allergic reaction may include: What VERSATIS Dermal shortness of breath If you have not told your doctor Patch is used for wheezing or difficulty breathing about any of the above, tell swelling of the face, lips, tongue him/her before you start using VERSATIS Dermal Patch contains or other parts of the body VERSATIS Dermal Patch. lidocaine, a local anaesthetic, which rash, itching or hives on the skin works by reducing the pain in your Taking other medicines skin. Do not use VERSATIS Dermal Patch: Tell your doctor if you are You have been given it to treat a on injured skin or open wounds taking any other medicines, painful skin condition called post- on the eyes or mouth including any that you buy herpetic neuralgia. This is the pain on unhealed shingles blisters without a prescription from a which persists after Herpes Zoster pharmacy, supermarket or (Shingles) infection. It is generally Do not give VERSATIS Dermal health food shop. characterised by localised Patch to children. symptoms such as burning, Safety and effectiveness in children Some medicines may be affected by shooting or stabbing pain. younger than 18 years has not been VERSATIS Dermal Patch, or may established. affect how well it works. These Ask your doctor if you have any include: questions about why VERSATIS Do not use VERSATIS Dermal Dermal Patch has been Patch if the expiry date (Exp.) some drugs used to slow the prescribed for you. printed on the pack has passed. heart, including tocainide and mexiletine Your doctor may have prescribed it other local anaesthetics such as for another reason. Do not use VERSATIS Dermal bupivacaine, etidocaine, Patch if the packaging is torn or mepivacaine or prilocaine. shows signs of tampering. Version3 March 202 Page 1 of 5 If you are not sure whether you Dermal Patch to the affected are taking any of these area medicines, check with your doctor or pharmacist. Cut any hairs on the affected skin using scissors. Do not shave Your doctor and pharmacist have hairs off. more information on medicines to Ensure the skin is clean and dry. be careful with or avoid while using VERSATIS Dermal Patch. Creams and lotions may be used on the affected skin during the period tear open or cut the sachet when you are not wearing the along the dotted line patch. How to apply VERSATIS when using scissors, be careful not to damage the Dermal Patch Allow your skin to cool off after a patches bath or shower. take out one or more Follow all directions given to patches depending on the you by your doctor or VERSATIS Dermal Patch should size of the painful area on pharmacist carefully. only be used on the areas of your skin skin after the shingles rash has If you do not understand the healed. It should not be used instructions in this leaflet, ask on or near the mouth. your doctor or pharmacist for Step 2: close the sachet help. Avoid contact of VERSATIS Dermal Patch with the eye. If How much to use contact occurs, immediately wash the eye with water or The daily dose is between one and saline and protect it until three patches depending on the size sensation returns. of the painful area of your skin. Avoid the use of external heat VERSATIS Dermal Patch may be cut sources, such as heating pads into smaller pieces to fit the or electric blankets, as the affected area. close the sachet tightly effect of this has not been after use studied. Local heat may alter You should not use more than 3 the patch contains water, the absorption of lidocaine patches at the same time. and will dry out if the from the patch. sachet is not closed VERSATIS Dermal Patches properly. should be worn for no more than 12 hours per day. Applying How to apply VERSATIS the patches for a longer time or Dermal Patch Step 3: cut the patch, if using more than 3 patches per necessary day could cause serious Step 1: open the sachet and reactions. remove one or more patches The patches should be removed after 12 hours of use, so that you have a 12 hour period with no patch in place. Usually, you will feel some pain relief on the first day you use the patch, but it may take up to 2 - 4 weeks until the full pain-relief effect if required, cut the patch to of VERSATIS Dermal Patch is seen. the required size to fit the If after that time you still have a lot painful area of skin before of pain, talk to your doctor because removing the liner. the benefits of the treatment must be weighed against potential risks. Your doctor will check how well VERSATIS Dermal Patch is working at regular intervals. Before you apply VERSATIS Version3 March 202 Page 2 of 5 How long to use VERSATIS If you have more pain during the Dermal Patch for Step 4: remove the liner day than at night you might want to apply the patch at 7am in the Continue using it for as long as the morning, and remove it at 7pm in doctor tells you. the evening. If you use too much VERSATIS Bathing, showering and Dermal Patch (overdose) swimming Immediately telephone your If at all possible contact with water doctor, or the Poisons should be avoided whilst wearing Information Centre (telephone VERSATIS Dermal Patch. Bathing, 13 11 26) if you think you or remove the transparent showering or swimming can be anyone else may have used too liner from the patch done in the time period when you much VERSATIS Dermal Patch. try not to touch the sticky are not wearing the patch. If you Do this even if there are no part of the patch have had a recent bath or shower, signs of discomfort or you should wait until your skin cools poisoning. before applying the patch. Step 5: apply the patch and Symptoms of an overdose may press it firmly onto the skin If the patch comes off include: dizziness, vomiting drowsiness, taste disturbances or Very rarely the patch might fall off, loss of taste, seizures, dilated or come unstuck. If it does, try pupils, a low heart beat, changes in sticking it back on the same area. If the way the heart beats (faster, it does not stay on, remove it and slower, irregular), and shock. put a new patch on the same area. How to remove VERSATIS While you are using Dermal Patch VERSATIS Dermal Patch When changing the patch, remove the old patch slowly. If it does not Things you must do apply up to three patches come off easily, you can soak it in to the painful area of skin warm water for a few minutes Before starting any new press the patch onto your before removing it. medicine, tell your doctor or skin pharmacist that you are using press for at least 10 If you forget to remove the VERSATIS Dermal Patch. seconds to make sure the patch after 12 hours patch sticks firmly If irritation or burning make sure that all of it As soon as you remember, remove sensation occurs whilst you are sticks to your skin, the old patch. A new patch can be using the patch, it should be including the edges used again after 12 hours. removed. The area of irritation should remain Leave the patch on for 12 hours If you forget to use VERSATIS patch free until the irritation stops. only Dermal Patch Even a used VERSATIS Dermal If it is almost time for you to apply Patch contains a large amount the next patch dose, skip the one of lidocaine.
Load more

Recommended publications
  • (12) United States Patent (10) Patent No.: US 7.427.405 B2 Agrawal Et Al
    USOO7427405B2 (12) United States Patent (10) Patent No.: US 7.427.405 B2 Agrawal et al. (45) Date of Patent: Sep. 23, 2008 (54) IMMUNOSTIMULATORY Tokunaga et al., “Antitumor Activity of Deoxyribonucleic Acid Frac OLGONUCLEOTDE MULTIMERS tion from Mycobaterium bovis BCG. I. Isolation. Physicochemical Characterization, and Antitumor Activity”. J. Natl. Cancer Inst. 72: (75) Inventors: Sudhir Agrawal, Shrewsbury, MA (US); 955-962(1984). Pisetsky et al., “Stimulation of in vitro proliferation of murine lym Ekambar Kandimala, Southboro, MA phocytes by synthetic oligodeoxynucleotides'. Molecular Biology (US); Dong Yu, Westboro, MA (US) Reports 18:217-221 (1993). Krieg et al., “CpG motifs in bacterial DNA trigger direct B-cell (73) Assignee: Idera Pharmaceuticals, Inc., activation”, Nature 374: 546-549 (1995). Cambridge, MA (US) Sato et al., “Immunostimulatory DNA Sequence Necessary for Effective Intradermal Gene Immunization', Science 273: 352-354 (*) Notice: Subject to any disclaimer, the term of this (1996). patent is extended or adjusted under 35 Krieg et al., “CpG Motifs in Bacterial DNA and their Immune U.S.C. 154(b) by 209 days. Effects”, Annu. Rev. Immunol. 20: 709-760 (2002). Dalpke et al., “Immunopharmacology of CpG DNA'. Biol. Chem. (21) Appl. No.: 11/174,282 383: 1491-1500 (2002). Kandimala et al., “Towards Optimal Design of Second-Generation (22) Filed: Jul. 1, 2005 Immunomodulatory Oligonucleotides'. Curr. Opin. Mol. Ther. 4(2): 122-129 (2002). (65) Prior Publication Data Kandimala et al., “Immunomers-novel 3'-3'-Linked CpG Oligodeoxyribonucleotides as Potent Immunomodulatory Agents'. US 2006/OO19919 A1 Jan. 26, 2006 Nucleic Acids Res. 30: 4460-4469 (2002). Kandimala et al.
    [Show full text]
  • Journal of Arthroscopy and Joint Surgery 6 (2019) 98E102
    Journal of Arthroscopy and Joint Surgery 6 (2019) 98e102 Contents lists available at ScienceDirect Journal of Arthroscopy and Joint Surgery journal homepage: www.elsevier.com/locate/jajs Comparative evaluation of periarticular infiltration of two cocktail regimens for analgesia in post-operative patients of total knee replacement * V.K. Gautam a, Ajeet Kumar a, Munisha Agarwal b, Bushu Harna a, , Rishabh Saini a, Siddharth Sharma a, Dhananjaya Sabat a a Dept. of Orthopaedics, Maulana Azad Medical College, New Delhi, India b Dept. of Anaesthesia, Maulana Azad Medical College, New Delhi, India article info abstract Article history: Purpose: To compare the efficacy of two periarticular cocktail regimens for analgesia in postoperative Received 30 April 2018 patients of total knee replacement. Received in revised form Method: This is a Randomized Control study done over the duration of 1.5 years. Twenty-five knees of 28 October 2018 either gender were selected with inclusion criteria (All osteoarthritis patients planned for TKA) and Accepted 9 November 2018 exclusion criteria (Inflammatory arthritis, patients allergic to local anaesthetic e.g. Ropivacaine, bupi- Available online 19 November 2018 vacaine, known cardiac disorder patient having AV block, arrhythmia) & divided into 2 groups. Group A was given a cocktail of Ropivacaine, adrenaline, clonidine & cefuroxime. Keywords: & Periarticular Group B was given a cocktail of bupivacaine, fentanyl, methylprednisolone cefuroxime. The preoper- Multimodal approach ative pain of the patient was assessed using VAS score. Combined spinal and epidural anaesthesia was Perioperative analgesia given using 0.5% 2 ml of bupivacaine heavy in all patients. After taking bone cuts & before the placement Corticosteroids of the implant, cocktail of the drug was infiltrated using sterile technique into 9 specific sites.
    [Show full text]
  • Adverse Effects of Xenogenic Scaffolding in the Context of A
    Lamas et al. Trials (2019) 20:387 https://doi.org/10.1186/s13063-019-3504-3 RESEARCH Open Access Adverse effects of xenogenic scaffolding in the context of a randomized double-blind placebo-controlled study for repairing full- thickness rotator cuff tears José Ramón Lamas1†, Carlos García-Fernández2, Pilar Tornero-Esteban1, Yaiza Lópiz2, Luis Rodriguez-Rodriguez1, Luis Ortega3, Benjamín Fernández-Gutiérrez1*† and Fernando Marco2† Abstract Purpose: The purpose of the study was to compare the safety and efficacy of autologous mesenchymal stem cells (MSCs) embedded in a xenogenic scaffold for repairing the supraspinatus tendon. Methods: This was a randomized, double-blind and placebo-controlled trial evaluating patients with full-thickness rotator cuff tears (Eudra-CT, 2007–007630-19). Effectiveness was evaluated using the Constant score and a visual analogue pain scale (VAS). Constant score has four domains including pain (15 possible points), activities of daily living (20 possible points), mobility (40 possible points), and strength (25 possible points). Scores range from 0 points (most disability) to 100 points (least disability). The structural integrity of the repaired tendon was assessed by magnetic resonance imaging (MRI) according to Patte and Thomazeau classification criteria. The primary study end point was an improvement in the Constant score by 20 points at one year compared to initial assessment. Results: The trial was stopped due to adverse effects observed in both groups. Only thirteen patients were included and analyzed. The Constant questionnaire showed a significant improvement in the MSC treatment group compared with the preoperative data (p = 0.0073). Secondary outcome measures were similar in both groups.
    [Show full text]
  • New Zealand Regulatory Guidelines for Medicines
    New Zealand Regulatory Guidelines for Medicines Part G: Resources Edition 6.13 March 2011 (consolidation of fifth edition and subsequent updates) Table of Contents PART G: RESOURCES Section 1: Description of Dosage Form...............................................................................2 Section 2: Routes of Administration....................................................................................4 Section 3: Shelf Life and Storage Conditions .....................................................................5 Section 4: Abbreviations.......................................................................................................6 Description of Dosage Form The dosage form description for a product should be selected from the following list: Block Granules, oral Capsule Implant, subcutaneous Capsule, combination Implant, intracranial Capsule, liquid filled Implant, intraocular Capsule, modified release Infusion, concentrate Capsule, powder filled Infusion, emulsion Capsule, powder filled, nasal inhalation Infusion, powder for Capsule, soft gelatin Infusion, powder for concentrate Cement, bone, liquid component Infusion, solution Cement, bone, powder component Inhalation, capsule, liquid filled Cement, dental Inhalation, capsule, powder filled Chewing gum Inhalation, powder Chocolate, medicated Inhalation, solution Combination Inhalation, solution, powder for Condom, medicated Inhalation, suspension Condom with spermicide Inhalation, volatile liquid Cream, rectal Inhaler, aerosol, metered Cream, topical Injection
    [Show full text]
  • JMSCR Vol||05||Issue||01||Page 15625-15629||January 2017
    JMSCR Vol||05||Issue||01||Page 15625-15629||January 2017 www.jmscr.igmpublication.org Impact Factor 5.84 Index Copernicus Value: 83.27 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v5i1.71 Transdermal Patch: A Comprehensive Overview of Newer Drug Delivery System in Modern Medical Science Authors Dr Neelkanth Kote1, Dr. Poornima B2 Department of Physiology and Department of Pharmacology Raja Rajeswari Medical Collegeand Hospital Bangalore, Karnataka– 560074 Corresponding Author Dr Neelkanth Kote Department of Physiology, RRMC Bangalore, Karnataka -560074 Email: [email protected] Abstract Background: Oral route of drug administration has been the most common route of drug administration since the beginning of the therapeuticarea in medical science. However this route of drug administration fails at bypassing the first pass metabolism of the drug in liver with poor bio availability. Oral route of drug administration also fails in uncooperative /unconscious semiconscious / pediatric subjects. Transdermal patch, a new drug delivery system through skin to the parenteral circulation has been the most recently discussed topic in pharmacology and medicine as it is a noninvasive route of drug administration, delivered in a sustained / pre fixed dosage with no / extremely less first pass metabolism and better bio availability. Most importantly it can be used in semiconscious / unconscious & pediatric subjects without affecting their hemodynamics. The transdermal patches have many beneficial factors however they also come with some major drawbacks like varieties of formulation, design and quality of adhesiveness. This articles provides an insight of transdermal patch in terms of its mechanism of action, advantages, disadvantages and future scope of it in the medical science.
    [Show full text]
  • WV Medical Cannabis Act
    Medical Cannabis Overview Legalized Marijuana • Medical marijuana is legal in 33 states and D.C. • Recreational marijuana is legal in 10 states and D.C. The Endocannabinoid System (ECS) • Anandamide (AEA) • Arachidonoylgycerol (2-AG) • Receptors: • CB1 • CB2 Cannabinoids • Three principle cannabinoids in cannabis: • Tetrahydrocannibinol (THC) • Cannabidiol (CBD)—the primary cannabinoid in medical marijuana • Cannabinol (CBN) Dr. Ralph Mechoulam GW Pharmaceuticals • Epidiolex—purified CBD used to control seizures • Sativex—for treatment of spasticity due to MS WV Medical Cannabis Act • Becomes effective July 1, 2019 • To be implemented and administered by Public Heath Bureau • Requires a “serious medical condition” to be certified Qualifying Medical Conditions • Cancer • Huntington’s disease • HIV • Crohn’s Disease • Amyotrophic lateral • PTSD sclerosis • Intractable seizures • Parkinson’s • Sickle cell anemia • MS • Severe chronic pain • Spinal cord damage • Terminally ill • Epilepsy • Neuropathies Lawful Use • Medical cannabis may only be dispensed to: • A patient who receives a certification from a practitioner and is in possession of a valid ID card from bureau • A caregiver in possession of valid ID card from bureau Acceptable Forms • Pill • Oil • Topical forms, including gels, creams, or ointment • A form medical appropriate for administration by vaporization or nebulization (excluding dry leaf or plant form) • Tincture • Liquid • Dermal patch Unlawful Use • Smoking and edible cannabis • No joints or brownies • Growing, unless the
    [Show full text]
  • WO 2017/172802 Al 5 October 2017 (05.10.2017) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/172802 Al 5 October 2017 (05.10.2017) P O P C T (51) International Patent Classification: 1 DNA Way, South San Francisco, California 94080-4990 C07C 381/10 (2006.01) C07D 211/22 (2006.01) (US). C07D 401/12 (2006.01) C07D 211/42 (2006.01) (74) Agents: HARRIS, Robert J. et al; Viksnins Harris & C07D 205/04 (2006.01) C07D 213/69 (2006.01) Padys PLLP, 785 1 Metro Parkway, Suite 325, Blooming- (21) International Application Number: ton, Minnesota 55425 (US). PCT/US2017/024584 (81) Designated States (unless otherwise indicated, for every (22) International Filing Date: kind of national protection available): AE, AG, AL, AM, 28 March 2017 (28.03.2017) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, (25) Filing Language: English DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (26) Publication Language: English HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, (30) Priority Data: MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, 62/3 15,469 30 March 2016 (30.03.2016) US NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, (71) Applicants: GENENTECH, INC. [US/US]; 1 DNA Way, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, South San Francisco, California 94080-4990 (US).
    [Show full text]
  • Literature and Registry Review
    _____________________________________________________________________________________ Literature and Registry Review 2005 - 2015 ______________________________________________________________________ “HEMICAP RESURFACING PROVIDES A UNIQUE AND FAVORABLE ALTERNATIVE TO PRIOR IMPLANT DESIGNS BY PROVIDING ANATOMIC RE-APPROXIMATION” Patellofemoral Kinematics After Limited Resurfacing of the Trochlea. Provencher M, Ghodadra N, Verma N, Cole BJ, Zaire S, Shewman E, Bach B. J Knee Surg. 2009;22:310-316 ______________________________________________________________________ Matthias R. Schurhoff _____________________________________________________________________________________ Arthrosurface Literature and Registry Review 2005-2015 _____________________________________________________________________________________________ Foreword his report is a review of the past decade outlining the introduction of inlay arthroplasty for arthrosis, early T arthritis and traumatic lesions. Arthrosurface, Inc. (Franklin, MA) was launched in 2002 bringing innovation and a sports medicine approach to primary arthroplasty. In the past decade, Arthrosurface has invested and re-invested more than $100 Million dollars in the development and commercialization of patient specific joint solutions that place the individual patient at the forefront of clinical decision making. The intraoperative choice of implant diameters and contour shapes allow the surgeon to not only cover the defect effectively, but also fit the implant to the patient while preserving healthy bone
    [Show full text]
  • Transdermal Drug Delivery System: a Review
    Indian Journal of Pharmacy and Pharmacology 2021;8(1):5–9 Content available at: https://www.ipinnovative.com/open-access-journals Indian Journal of Pharmacy and Pharmacology Journal homepage: https://www.ijpp.org.in/ Review Article Transdermal drug delivery system: A review Neha Choudhary1,*, Ajeet Pal Singh1, Amar Pal Singh1 1St. Soldier Institute of Pharmacy, Lidhran Campus, Jalandhar, Punjab, India ARTICLEINFO ABSTRACT Article history: Transdermal Drug Delivery System is controlled medicated that is set on the skin to deliver a particular Received 15-03-2021 portion of medicine through the skin and into the circulatory system. It is likewise significant because of its Accepted 17-03-2021 interesting benefit such as less absorption, more uniform plasma levels, improved bioavailability, decrease Available online 19-04-2021 side effect, efficacy and quality of the product. Transdermal dose structures may give clinicians a chance to offer more therapeutic alternatives to their patients to upgrade their consideration. Keywords: © This is an open access article distributed under the terms of the Creative Commons Attribution Advantages/Disadvantages License (https://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and Skin types reproduction in any medium, provided the original author and source are credited. Factors affecting permeation Components Evaluations 1. Introduction 4. Drug duration of action are extendable 5. GIT incompatibilities get avoided Now a day many drugs are administered orally, but they are 6. Number of dosage frequency reduced observed not more effective as desired so to upgrade such 7. Easier to remember and used character TDDS was created. Drug delivery administered 8. Large area of application in comparison with nasal and by the skin and attain a systemic effect of drug is called buccal cavity as transdermal drug delivery system.
    [Show full text]
  • A Fully Integrated Microneedle-Based Transdermal Drug Delivery System
    A Fully Integrated Microneedle-based Transdermal Drug Delivery System Niclas Roxhed MICROSYSTEM TECHNOLOGY LABORATORY SCHOOL OF ELECTRICAL ENGINEERING ROYAL INSTITUTE OF TECHNOLOGY ISBN 978-91-7178-751-4 ISSN 1653-5146 TRITA-EE 2007:046 Submitted to the School of Electrical Engineering KTH—Royal Institute of Technology, Stockholm, Sweden, in partial fulfillment of the requirements for the degree of Doctor of Philosophy Stockholm 2007 ii A Fully Integrated Microneedle-based Transdermal Drug Delivery System The left picture on the front cover shows an integrated microneedle-based drug delivery system fabricated and used for experiments by the author. An array of microneedles is located on the other side of the device. The right picture on the cover shows a magnified view of these side-opened hollow microneedles, likewise fabricated by the author. The needles are designed to penetrate skin tissue using a low insertion force. The needles are fabricated by deep reactive ion etching of silicon and the length of the needles is 400 μm. Copyright 2007 by Niclas Roxhed All rights reserved to the summary part of this thesis, including all pictures and figures. No part of this publication may be reproduced or transmitted in any form or by any means, without prior permission in writing from the copyright holder. The copyrights for the appended journal papers belong to the publishing houses of the journals concerned. The copyrights for the appended manuscripts belong to their authors. Printed by Universitetsservice US AB, Stockholm 2007. Thesis for the degree of Doctor of Philosophy at the Royal Institute of Technology, Stockholm, Sweden, 2007.
    [Show full text]
  • How to Treat Nicotine Dependence in Smokers with Schizophrenia
    pSYCHIATRY How to treat nicotine dependence in smokers with schizophrenia Improve patients’ health, help them kick addiction with this practical approach r. V, age 49, has stable but ®symptomaticDowden Health Media schizophrenia and a 33-year cigarette smoking Mhistory. He is very concerned because his primary care physicianCopyright told him heFor has personal2 serious use only smoking-related health problems: diabetes and hypertension. He tried a smoking cessation program for the general public, but it was a poor fit because of his schizophrenia symptoms. Despite adhering to his medications (ziprasidone, 20 mg hs; perphenazine, 8 mg hs; lorazepam, 1 mg hs; zonisamide, 200 mg/d, and benztropine mesylate, 2 mg hs), Mr. V has residual auditory hallucinations, paranoid ideation, and impaired concentration and attention. He smokes approximately 1.5 packs per day, particularly when VEER.COM very ill, to alleviate chronic boredom, and to diminish 2007 © distress from the hallucinations. All of his friends smoke, and they do not support his attempts to quit. Jennifer D. Gottlieb, PhD Schizophrenia clinical and research program Massachusetts General Hospital Successfully treating nicotine dependence can seem a Instructor in psychiatry formidable challenge in patients with schizophrenia: Harvard Medical School • 72% to 90% smoke cigarettes, compared with 21% A. Eden Evins, MD, MPH of the general population1 (Box, page 66).2-12 Schizophrenia and depression clinical and research programs • They tend to smoke heavily, spending about one- Director, Center for Addiction Medicine third of their incomes on cigarettes.13 and addiction research program • Their negative symptoms (such as apathy), posi- Massachusetts General Hospital Assistant professor of psychiatry tive symptoms (such as disorganized thinking), Harvard Medical School and cognitive impairment can reduce motivation to quit and adhere to a smoking cessation strategy.
    [Show full text]
  • How a Painless Patch Could One Day Deliver Vaccines
    How a painless patch could one day deliver vaccines pbs.org/newshour/health/how-a-painless-patch-could-one-day-deliver-vaccines Isabella Isaacs-Thomas July 31, 2020 When you pull up your sleeve to get your yearly flu shot, you might feel a twinge of anxiety as a health care provider readies the needle and syringe. Maybe you find yourself looking away or taking deep breaths to steel yourself, even though it’s over in just a few seconds. So what if there was a painless vaccine you could administer yourself? What if, rather than heading to the pharmacy, you could simply place the equivalent of a Band-Aid on your arm, leave it there for a few minutes to a few hours, then take it off and let your physician know you’ve been innoculated? That’s one of the main goals of vaccine patch technology. Multiple research teams have designed patches that use microneedle arrays made out of materials like stainless steel or sugar to deliver quick and pain-free vaccination by taking advantage of the key role that skin plays in training our immune system. One group is even developing a completely needle-free method to confer immunity. Vaccination is a crucial public health measure against serious, preventable illnesses, but the fear of needles — or of vaccines themselves — can be a hurdle to protection for individuals and their communities. In many places around the world, extreme conditions or lack of health care can stifle accessibility to traditional vaccines, too. Vaccine patches haven’t yet been approved for commercial use, but both global vaccine experts and researchers have acknowledged their potential for years, particularly when it comes to making vaccines more accessible worldwide.
    [Show full text]